13.84
price down icon2.88%   -0.41
pre-market  プレマーケット:  13.84  
loading
前日終値:
$14.25
開ける:
$14.03
24時間の取引高:
155.42K
Relative Volume:
0.53
時価総額:
$401.62M
収益:
$66.59M
当期純損益:
$-104.93M
株価収益率:
-2.796
EPS:
-4.95
ネットキャッシュフロー:
$-96.48M
1週間 パフォーマンス:
+6.71%
1か月 パフォーマンス:
+7.20%
6か月 パフォーマンス:
+101.75%
1年 パフォーマンス:
+136.18%
1日の値動き範囲:
Value
$13.82
$14.38
1週間の範囲:
Value
$13.18
$15.55
52週間の値動き範囲:
Value
$4.09
$17.15

Enanta Pharmaceuticals Inc Stock (ENTA) Company Profile

Name
名前
Enanta Pharmaceuticals Inc
Name
セクター
Healthcare (1112)
Name
電話
617 607 0800
Name
住所
4 KINGSBURY AVENUE, WATERTOWN, MA
Name
職員
120
Name
Twitter
@EnantaPharma
Name
次回の収益日
2025-02-10
Name
最新のSEC提出書
Name
ENTA's Discussions on Twitter

Compare ENTA vs VRTX, REGN, ARGX, ALNY, ONC

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
ENTA
Enanta Pharmaceuticals Inc
13.84 413.51M 66.59M -104.93M -96.48M -4.95
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
465.02 117.03B 11.74B 3.68B 3.34B 14.19
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
783.65 82.35B 14.34B 4.50B 3.77B 41.56
Biotechnology icon
ARGX
Argen X Se Adr
833.54 51.64B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
308.48 42.58B 3.21B 43.57M 221.36M 0.2405
Biotechnology icon
ONC
Beone Medicines Ltd Adr
346.42 38.87B 4.98B 69.60M 525.67M 0.5198

Enanta Pharmaceuticals Inc Stock (ENTA) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-11-14 開始されました JP Morgan Overweight
2025-10-01 アップグレード Jefferies Hold → Buy
2025-07-28 再開されました H.C. Wainwright Buy
2023-08-09 ダウングレード JP Morgan Neutral → Underweight
2023-08-08 ダウングレード Jefferies Buy → Hold
2022-12-09 開始されました H.C. Wainwright Buy
2022-07-06 アップグレード Evercore ISI In-line → Outperform
2022-06-01 アップグレード Evercore ISI Underperform → In-line
2021-10-07 開始されました Jefferies Buy
2021-09-09 開始されました SVB Leerink Mkt Perform
2021-01-29 アップグレード JP Morgan Underweight → Neutral
2020-11-24 開始されました Evercore ISI Underperform
2020-08-28 再開されました ROTH Capital Buy
2020-08-26 開始されました Piper Sandler Overweight
2020-07-27 アップグレード JMP Securities Mkt Perform → Mkt Outperform
2020-03-17 アップグレード Robert W. Baird Neutral → Outperform
2019-11-22 ダウングレード JMP Securities Mkt Outperform → Mkt Perform
2019-09-26 ダウングレード JP Morgan Neutral → Underweight
2019-05-24 開始されました Wolfe Research Outperform
2019-04-23 アップグレード Berenberg Hold → Buy
2018-12-13 開始されました Berenberg Hold
2018-06-06 開始されました ROTH Capital Buy
2018-02-08 ダウングレード JP Morgan Overweight → Neutral
2018-01-02 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2017-11-21 繰り返されました RBC Capital Mkts Outperform
2017-09-15 開始されました RBC Capital Mkts Outperform
2017-07-11 アップグレード JMP Securities Mkt Perform → Mkt Outperform
2016-04-28 ダウングレード JMP Securities Mkt Outperform → Mkt Perform
2016-02-09 繰り返されました Barclays Underweight
2015-10-23 ダウングレード Barclays Equal Weight → Underweight
2015-10-23 アップグレード JMP Securities Mkt Perform → Mkt Outperform
すべてを表示

Enanta Pharmaceuticals Inc (ENTA) 最新ニュース

pulisher
Feb 12, 2026

What Makes Enanta Pharmaceuticals (ENTA) a New Buy Stock - Yahoo Finance

Feb 12, 2026
pulisher
Feb 12, 2026

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat

Feb 12, 2026
pulisher
Feb 12, 2026

Equities Analysts Issue Forecasts for ENTA Q2 Earnings - MarketBeat

Feb 12, 2026
pulisher
Feb 12, 2026

Analysts Are Updating Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Estimates After Its First-Quarter Results - simplywall.st

Feb 12, 2026
pulisher
Feb 12, 2026

The Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) First-Quarter Results Are Out And Analysts Have Published New Forecasts - 富途牛牛

Feb 12, 2026
pulisher
Feb 11, 2026

Enanta (ENTA) Announces $150 Million Mixed Securities Shelf Registration - GuruFocus

Feb 11, 2026
pulisher
Feb 10, 2026

Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for - PharmiWeb.com

Feb 10, 2026
pulisher
Feb 10, 2026

Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Type 2 Immune Diseases, at the 2026 AAAAI Annual Meeting - BioSpace

Feb 10, 2026
pulisher
Feb 10, 2026

Enanta Pharma (ENTA): Analyst Reiterates Buy Rating with $20 PT - GuruFocus

Feb 10, 2026
pulisher
Feb 10, 2026

HC Wainwright Reaffirms "Buy" Rating for Enanta Pharmaceuticals (NASDAQ:ENTA) - MarketBeat

Feb 10, 2026
pulisher
Feb 10, 2026

Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2025 - BioSpace

Feb 10, 2026
pulisher
Feb 09, 2026

Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 202 - PharmiWeb.com

Feb 09, 2026
pulisher
Feb 09, 2026

Enanta Pharmaceuticals (ENTA) Reports Strong Q1 Revenue and Fina - GuruFocus

Feb 09, 2026
pulisher
Feb 09, 2026

Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance

Feb 09, 2026
pulisher
Feb 09, 2026

Enanta Pharmaceuticals (NASDAQ:ENTA) Posts Earnings Results, Beats Estimates By $0.12 EPS - MarketBeat

Feb 09, 2026
pulisher
Feb 09, 2026

Enanta Pharmaceuticals: Fiscal Q1 Earnings Snapshot - KVUE

Feb 09, 2026
pulisher
Feb 09, 2026

Enanta Pharmaceuticals: Overview of Fiscal First Quarter Earnings - Bitget

Feb 09, 2026
pulisher
Feb 09, 2026

Enanta Pharma Earnings Review: Q1 Summary - Benzinga

Feb 09, 2026
pulisher
Feb 09, 2026

The Technical Signals Behind (ENTA) That Institutions Follow - Stock Traders Daily

Feb 09, 2026
pulisher
Feb 06, 2026

Earnings Preview For Enanta Pharma - Benzinga

Feb 06, 2026
pulisher
Feb 02, 2026

Enanta Pharmaceuticals (ENTA) Projected to Post Quarterly Earnings on Monday - MarketBeat

Feb 02, 2026
pulisher
Jan 30, 2026

Rate Hike: Does Enanta Pharmaceuticals Inc have consistent dividend growthPortfolio Performance Report & Fast Exit Strategy with Risk Control - baoquankhu1.vn

Jan 30, 2026
pulisher
Jan 29, 2026

Insider Sell: What are Asset Entities Incs technical support levelsMarket Trend Report & High Accuracy Trade Alerts - baoquankhu1.vn

Jan 29, 2026
pulisher
Jan 29, 2026

Precision Trading with Enanta Pharmaceuticals Inc. (ENTA) Risk Zones - Stock Traders Daily

Jan 29, 2026
pulisher
Jan 26, 2026

Enanta (NASDAQ: ENTA) seeks 1.6M-share boost to 2019 equity plan - Stock Titan

Jan 26, 2026
pulisher
Jan 24, 2026

CEO Moves: Why is Enanta Pharmaceuticals Inc stock going up2025 Market WrapUp & AI Optimized Trading Strategy Guides - baoquankhu1.vn

Jan 24, 2026
pulisher
Jan 21, 2026

Sentiment Review: What are Enanta Pharmaceuticals Inc.’s technical support levelsDividend Hike & Low Risk High Reward Trade Ideas - baoquankhu1.vn

Jan 21, 2026
pulisher
Jan 21, 2026

Guidance Update: Why is SWKH stock going downSwing Trade & Verified Short-Term Plans - baoquankhu1.vn

Jan 21, 2026
pulisher
Jan 19, 2026

Enanta Pharmaceuticals to Present at the Wells Fargo Securities 2013 Healthcare Conference - AOL.com

Jan 19, 2026
pulisher
Jan 18, 2026

Why Enanta Pharmaceuticals Inc. stock appeals to analystsJobs Report & Free Long-Term Investment Growth Plans - bollywoodhelpline.com

Jan 18, 2026
pulisher
Jan 18, 2026

Technical Reactions to ENTA Trends in Macro Strategies - Stock Traders Daily

Jan 18, 2026
pulisher
Jan 18, 2026

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat

Jan 18, 2026
pulisher
Jan 15, 2026

JPM26: Enanta outlines strategy to lead in RSV therapeutics - Yahoo Finance

Jan 15, 2026
pulisher
Jan 13, 2026

Chipmakers Recap: Is Enanta Pharmaceuticals Inc stock affected by interest rate hikesPortfolio Update Report & Free Technical Pattern Based Buy Signals - Bộ Nội Vụ

Jan 13, 2026
pulisher
Jan 13, 2026

Income Plays: What makes Enanta Pharmaceuticals Inc. stock attractive to growth fundsJuly 2025 Market Mood & Growth Focused Entry Point Reports - Bộ Nội Vụ

Jan 13, 2026
pulisher
Jan 12, 2026

Downgrade Watch: Why is Enanta Pharmaceuticals Inc stock going upJuly 2025 Summary & Trade Opportunity Analysis - baoquankhu1.vn

Jan 12, 2026
pulisher
Jan 10, 2026

Is Enanta Pharmaceuticals Inc. stock trading at a premium valuationJuly 2025 Trade Ideas & Reliable Trade Execution Plans - ulpravda.ru

Jan 10, 2026
pulisher
Jan 10, 2026

Will Enanta Pharmaceuticals Inc. stock gain from strong economyAnalyst Downgrade & Safe Swing Trade Setups - Улправда

Jan 10, 2026
pulisher
Jan 10, 2026

Enanta Pharmaceuticals, Inc.Common Stock (NQ: ENTA - FinancialContent

Jan 10, 2026
pulisher
Jan 09, 2026

What makes Enanta Pharmaceuticals Inc. stock attractive to growth fundsTrade Execution Strategies & Our Experts Decode Market Noise for You - bollywoodhelpline.com

Jan 09, 2026
pulisher
Jan 09, 2026

Enanta advances RSV and immunology pipeline with key milestones ahead By Investing.com - Investing.com Nigeria

Jan 09, 2026
pulisher
Jan 09, 2026

Enanta Pharmaceuticals (NASDAQ:ENTA) Receives "Buy" Rating from HC Wainwright - MarketBeat

Jan 09, 2026
pulisher
Jan 09, 2026

Enanta Pharma (ENTA) Receives Buy Rating, Price Target Maintained | ENTA Stock News - GuruFocus

Jan 09, 2026
pulisher
Jan 09, 2026

Baird reiterates Outperform rating on Enanta Pharmaceuticals stock By Investing.com - Investing.com Canada

Jan 09, 2026
pulisher
Jan 08, 2026

Will Enanta Pharmaceuticals Inc. stock benefit from automationQuarterly Portfolio Summary & Daily Oversold Bounce Ideas - Улправда

Jan 08, 2026
pulisher
Jan 08, 2026

Is Enanta Pharmaceuticals Inc. stock a safe haven assetWeekly Trend Report & Weekly Stock Breakout Alerts - ulpravda.ru

Jan 08, 2026
pulisher
Jan 08, 2026

What valuation multiples suggest for Enanta Pharmaceuticals Inc. stock2025 Breakouts & Breakdowns & Fast Moving Market Watchlists - Улправда

Jan 08, 2026
pulisher
Jan 08, 2026

Is Enanta Pharmaceuticals Inc. stock a bargain at current levelsJuly 2025 Rallies & Risk Controlled Daily Plans - Улправда

Jan 08, 2026
pulisher
Jan 08, 2026

Enanta Pharmaceuticals Provides Update on its Research and Development Programs and 2026 Outlook - PharmiWeb.com

Jan 08, 2026
pulisher
Jan 08, 2026

Enanta advances RSV and immunology pipeline with key milestones ahead - Investing.com

Jan 08, 2026
pulisher
Jan 07, 2026

Trading the Move, Not the Narrative: (ENTA) Edition - Stock Traders Daily

Jan 07, 2026

Enanta Pharmaceuticals Inc (ENTA) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$44.80
price up icon 1.24%
$26.75
price down icon 0.19%
$100.75
price up icon 1.93%
$105.76
price down icon 3.31%
$146.17
price down icon 1.52%
biotechnology ONC
$346.42
price down icon 1.38%
大文字化:     |  ボリューム (24 時間):